Q2 2025 revenue grew 6.6% YoY to SAR 380 million, driven by strong outpatient and acute specialty growth, despite a strategic phase-out of LTC beds. Margins were impacted by one-off IPO and restructuring costs, but guidance for FY 2025 is reaffirmed, with expansion plans on track.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.